Immucor/Gamma Biologicals
This article was originally published in The Gray Sheet
Executive Summary
Merger agreement valued at $25 mil. calls for Immucor to launch a cash tender offer for all outstanding GB shares at $5.40 each. The combination would make Immucor "the market leader in providing blood serology reagents and systems in the U.S. and Canada, and will greatly strengthen its international market position," Immucor states. The tender offer, begun Sept. 25, is expected to close Oct. 23, whereupon GB will become a wholly owned subsidiary of Immucor. Stock in GB, which posted fiscal 1998 revenues of $18 mil., closed at $3 on Sept. 18, the last trading day before the announcement
You may also be interested in...
Diagnostics In Brief
Siemens/Dade deal: Siemens expects to close its $7 billion acquisition of diagnostics firm Dade Behring Nov. 6, ahead of initial expectations. The announcement follows expiration of the $77 per share cash tender offer on Oct. 31. Dade CEO Jim Reid-Anderson will become the new chief of Siemens Medical Solutions Diagnostics. The division is currently headed by Tony Bihl, former president of Bayer Diagnostics, which Siemens acquired in January. Primary offices will be located at Dade's headquarters in Deerfield, Ill. Dade recently reported third-quarter sales of $475 million, up 12% over the prior-year period. Upon completion of the deal, Siemens is expected to overtake Roche Diagnostics as the in vitro diagnostics market leader (1"The Gray Sheet" July 30, 2007, p. 4)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.